<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.business-standard.com/article/pti-stories/lupin-launches-generic-hypokalemia-drug-in-us-119111900880_1.html"/>
    <meta property="og:site_name" content="Business-Standard"/>
    <meta property="article:published_time" content="2019-11-19T10:02:00+00:00"/>
    <meta property="og:title" content="Lupin launches generic drug in US for treatment, prevention of hypokalemia"/>
    <meta property="og:description" content="The company had earlier received approval for the product from the United States Food and Drug Administration"/>
  </head>
  <body>
    <article>
      <h1>Lupin launches generic drug in US for treatment, prevention of hypokalemia</h1>
      <h2>The company had earlier received approval for the product from the United States Food and Drug Administration</h2>
      <address><time datetime="2019-11-19T10:02:00+00:00">19 Nov 2019, 10:02</time> by <a rel="author">Press Trust of India</a></address>
      <p>Pharma firm <a href="https://www.business-standard.com/topic/lupin">Lupin </a>on Tuesday said it has launched in the US generic potassium chloride for oral solution used for treatment and prevention of hypokalemia.</p>
      <p>The company had earlier received approval for the product from the United States Food and Drug Administration (USFDA), <a href="https://www.business-standard.com/topic/lupin">Lupin </a>said in a statement.</p>
      <p>Lupin's potassium chloride for oral solution USP, 20 mEq, is the generic version of Pharma Research Software Solution LLC's potassium chloride for oral solution USP in the same strength, it added.</p>
      <p>As per IQVIA MAT September 2019 data, potassium chloride for oral solution USP, 20 mEq had an annual sale of around USD 90 million in the US, <a href="https://www.business-standard.com/topic/lupin">Lupin </a>said.</p>
      <p>The product "is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient," it added.</p>
      <p>Shares of Lupin were trading at Rs 747 per scrip on the BSE, up 0.09 per cent from the previous close.</p>
    </article>
  </body>
</html>